Post-market Multi-Center RETRO-Prospective Study to Assess Long-term Clinical Outcomes NMSC Patients Treated With eBx

Completed

Conditions studied: Non-melanoma Skin Cancer

In brief

The purpose of this retrospective-prospective study is to evaluate lesions after treatment for BCC or SCC NMSC in order to gain a better understanding of the durability of the treatment, and risk of late toxicities for this patient population.

Key facts

Study ID

NCT05257486

Run by

Xoft, Inc.

People needed

183

Starts

2022-03-09

Expected to finish

2022-10-13

Last updated by the study team

2025-01-13

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Previously completed treatment for non-melanoma skin cancer using Xoft eBx Electronic Brachytherapy System according to standard of care;16
• Provides informed consent;
• Greater than 40 years of age;
• Pathological diagnosis confirmed to be squamous cell carcinoma, or squamous cell carcinoma-in-situ, or basal cell carcinoma prior to treatment;
• Cancer Staging included in this study:
• Stage 0: Tis, N0, M0 Stage 1: T1a, b, c, N0, M0 Stage 2: T2a, N0, M0

You may not qualify if…

• Target area is adjacent to a burn scar;
• Any prior definitive surgical resection of the cancer, prior to Radiation Treatment;
• Known perineural invasion;
• Actinic Keratosis;
• Known spread to regional lymph nodes;
• Known metastatic disease;
• Lesion treated with Mohs surgery.

Where it is running

• Kenneth A. Miller, MD Dermatology — Campbell, California, United States
• Dermatology & Laser Center of San Diego — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.